Walter P. Scheffe Continuing Pharmaceutical Education Series

November 9-10, 2024

The University of Oklahoma College of Pharmacy | Room 101 1101 N. Stonewall Ave. Oklahoma City, Oklahoma 73117

Produced and hosted by:





The University of Oklahoma College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

Program Registration

Name	Practice Setting
1 tunic	Thedee Setting
NABP e-Profile ID	Birthday (MMDD)
THE CHOICE	Difficulty (IIIIIIII)
Email	Phone
	Thone
Workplace/Employer	Dietary Restrictions
" ompiace, Employer	Diedly Heddiedollo

Registration Costs

Pre-registration is \$150/day and will be accepted until 11/8/24. On-site registration is \$165/day. This includes all activity materials, continental breakfast, lunch and refreshments. Participants will be emailed a link to download/print program documents one week in advance. Wi-Fi will be available on-site for those who would like to follow along on their device.

I will download/print my own materials.	
I would like my materials printed for me.	
Payment Method	
Credit Card	Check (Include Check #)

Credit Card | Visit our secure website at: https://pharmacy.ouhsc.edu/marketplace → Alumni Store

Check | Mail with registration form to: OU College of Pharmacy P.O. Box 26901, CPB 104D, OKC, OK 73126

For questions regarding registration or accommodations, contact Cassidy-Roberts@ouhsc.edu / (405) 271-6194

November 9, 2024

8 contact hours (0.8 CEUs) total

7:30-7:55am **Registration & Breakfast**

7:55-8:00am Introduction

8:00-9:00am Immunization Updates 2024: Clinical and Regulatory Changes for Pharmacists* (K)

ACPE# 0053-0000-24-024-L06-P 1 contact hour (0.1 CEU) Susan Conway, Pharm.D., FASHP, BCACP

9:00-10:00am **The GLP-1 RA Face Off * (A)** *ACPE# 0053-0000-24-025-L01-P* 1 contact hour (0.1 CEU) *Taylor Spisany, Pharm.D., BCACP*

10:00-10:15am **Break**

10:15-12:15pm The Top of Your License: A Community Pharmacy Update* (K)

ACPE# 0053-0000-24-026-L04-P 2 contact hours (0.2 CEUs) David George, Pharm.D., Ph.D.

12:15-12:45pm **Lunch**

12:45-2:15pm It All Adds Up: Non-opioids, Opioids, and Adjuncts for Managing Pain in Pediatric Patients* (A)

ACPE# 0053-0000-24-027-L08-P 1.5 contact hours (0.15 CEUs) Pete Johnson, Pharm.D., BCPPS, FPPA, FCCM, FASHP

2:15-3:15pm Shifting from NASH to MASH: Key Updates in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease* (A)

ACPE# 0053-0000-24-028-L01-P 1 contact hour (0.1 CEU) Kiya Bennett, Pharm.D., BCPS

3:15-3:30pm **Break**

3:30-5:00pm Rhythm and Reason for Atrial Fibrillation Management* (A)

ACPE# 0053-0000-24-029-L01-P 1.5 contact hours (0.15 CEUs) Corey Guidry, Pharm.D., BCPS

5:00-5:05pm Closing Remarks & Evaluation

November 10, 2024

7 contact hours (0.7 CEUs) total

7:30-7:55am **Registration & Breakfast**

7:55-8:00am **Introduction**

8:00-9:30am Oklahoma State Board of Pharmacy 2024 Law Update* (K)

ACPE# 0053-0000-24-030-L03-P 1.5 contact hours (0.15 CEUs) Jennifer Musgrove, Pharm.D., D.Ph.

9:30-9:45am **Break**

9:45-11:45am Outcomes, Access, and Care among High-Need and Complex Patient Populations* (K)

ACPE# 0053-0000-24-031-L01-P 2 contact hours (0.2 CEUs) Grant Skrepnek, Ph.D., R.Ph.

11:45-12:15pm Lunch

12:15-1:45pm Sweet Success: Conquering Outpatient Diabetes Management* (A)

ACPE# 0053-0000-24-032-L01-P 1.5 contact hours (0.15 CEUs) Mary Shreffler, Pharm.D., BCPS

1:45-2:00pm **Break**

2:00-4:00pm A Toxic Situation: The Role of Pharmacists in Poison Prevention and Management* (A)

ACPE# 0053-0000-24-033-L01-P 2 contact hours (0.2 CEUs) Kristie Edelen, Pharm.D., DABAT

4:00-4:05pm Closing Remarks & Evaluation

CPE Credit

This seminar offers a total of 15 contact hours (1.5 CEUs) of ACPE-accredited continuing pharmacy education (CPE) credit accepted by all U.S. boards of pharmacy. Credit is earned based on attendance and participation in individually accredited activities. Partial credit will not be awarded. Those who arrive over 10 minutes late or leave early will not be granted credit. For successful attendance verification and activity completion, each participant must sign in on the morning and afternoon sign-in sheet, provide NABP e-Profile ID and birthday (MMDD), participate in the learning assessments, return nametag at the end of the final session attended, and complete the online program evaluation. The University of Oklahoma College of Pharmacy (OUCOP), as an ACPE-accredited provider, is required to report credit online through CPE Monitor. Credit will be uploaded within four weeks of the seminar and participants will be notified via email. The initial release date is 11/9/24 (Sat) and 11/10/24 (Sun).

Registration & Contact Info

Pre-registration is suggested to allow OUCOP to provide the appropriate faculty and materials necessary to meet the program objectives. Pre-registration is \$150/day and will be accepted until 11/8/24. We reserve the right to limit registrations or cancel courses. There are no refunds. For questions, concerns or grievances, please contact the OUCOP Continuing Education Administrator at Cassidy-Roberts@ouhsc.edu or (405) 271-6194.

*Denotes sessions of continuing education credit (K)=Knowledge-based (A)=Application-based

Continuing education activities are structured to meet knowledge- and/or application-based education needs. A knowledge-based activity is for participants to acquire factual knowledge. An application-based activity is for participants to apply the information learned in the allotted timeframe. Information in all CPE activities is based on evidence as accepted in the literature by the health care professions.

Target Audience & Learning Objectives

This continuing pharmacy education program is intended for pharmacists in any practice setting. At the completion of this activity, the participant will be able to:

ACPE # 0053-0000-24-024-L06-P (K)

List the indications, contraindications, and administration routes of newly approved and recently updated vaccines Summarize updates to immunization schedules and guidelines from the CDC, ACIP, and FDA

Explain the rationale behind recent changes and their implications for patient care

ACPE # 0053-0000-24-025-L01-P (A)

Compare equivalent dosing between the various GLP-1 RAs List the benefits of changing from one GLP-1 RA to another Apply recommendations for minimizing adverse effects of GLP-1 RA therapy

ACPE # 0053-0000-24-026-L04-P (K)

Summarize the recent progression of a community pharmacist's role

List clinical services that can enhance the community pharmacy setting

Outline opportunities to advance a pharmacist's contribution to the healthcare team

Locate available certifications and training resources to conduct effective clinical services

ACPE # 0053-0000-24-027-L08-P (A)

Recognize two differences in pain management for children compared with adults

Compare available pediatric pain assessment tools Identify seven recommendations from the Pediatric Pharmacy Association for opioid use in pediatric patients Choose appropriate opioid, over-the-counter, and adjunct

ACPE # 0053-0000-24-028-L01-P (A)

agents when given a patient case

Identify comorbid conditions associated with metabolic dysfunction-associated steatotic liver disease (MASLD)

Describe methods for patient screening, diagnosis, and disease state assessment for individuals with or at risk for MASLD Analyze the effectiveness of current treatment options and emerging therapies in managing advanced MASLD based on primary literature

Choose optimal treatment plans based on individual risk factors and guideline-directed recommendations for MASLD

ACPE # 0053-0000-24-029-L01-P (A)

Identify modifiable and non-modifiable risk factors, staging, and pillars for management of atrial fibrillation (AF)
Use various risk stratification tools for assessing stroke and bleeding risk in patients with AF

Examine the role of direct oral anticoagulants in the management of AF based on the latest evidence and recommendations Apply updated strategies for rate and rhythm control in patients with AF, including any changes in medication preferences or procedural interventions

ACPE # 0053-0000-24-030-L03-P (K)

Identify recent changes to Oklahoma State Board of Pharmacy laws and rules

Locate available resources to stay updated on current regulations Report common violations seen during annual pharmacy inspections

ACPE # 0053-0000-24-031-L01-P (K)

Classify key characteristics of high-need patient populations Outline the implications of high-need patient populations upon care delivery

Identify policies that support high-need patient care models Summarize strategies that pharmacists can employ to optimize outcomes for high-need patients

ACPE # 0053-0000-24-032-L01-P (A)

Identify risk factors and signs of overbasalization during insulin therapy

Apply strategies to support patients suffering from diabetes distress Analyze continuous glucose monitor data to optimize therapeutic management

ACPE # 0053-0000-24-033-L01-P (A)

Explain the role of pharmacists in poison prevention and management

Use appropriate antidotes to improve patient outcomes in cases of poisoning

Recognize when it is appropriate to seek consultation with the poison center

Identify toxidromes based on initial physical examination findings Formulate a treatment plan for a patient that presents with signs and symptoms of a particular toxidrome

The University of Oklahoma (QU) is an equal opportunity institution. Accommodations on the basis of disability are available by contacting Cassidy-Roberts@ouhsc.edu. We are committed to protecting the privacy of our learners. Your personal information will not be shared with anyone outside OUCOP unless you consented to your name and practice site being shared with vendor representatives, if applicable. In that case, no contact details or any other information will be given out. Resources are provided for the educational benefit of our learners and are not for distribution. All information and materials provided are the property of OU/OUCOP or is licensed or has been granted permission for use by the copyright owner. No materials may be reproduced or transmitted without written permission. All rights reserved. To access the entirety of these policies, visit https://ou.edu/marcomm/web-policies/termsofuse and https://ou.edu/eoo/policies-and-procedures.

Faculty

Kiya Bennett, Pharm.D., BCPS

Assistant Professor OU College of Pharmacy | OKC

Susan Conway, Pharm.D., FASHP, BCACP

Professor and Director of Experiential Education OU College of Pharmacy | OKC

Kristie Edelen, Pharm.D., DABAT

Managing Director Oklahoma Poison Center | OKC

David George, Pharm.D., Ph.D.

Director of Finance and Strategy TotalDose Pharmacy | Edmond

Corey Guidry, Pharm.D., BCPS

Assistant Professor OU College of Pharmacy | OKC

Pete Johnson, Pharm.D., BCPPS, FPPA, FASHP

Professor & President's Associate Presidential Professor OU College of Pharmacy | OKC

Jennifer Musgrove, Pharm.D., D.Ph.

Pharmacist Compliance Officer Oklahoma State Board of Pharmacy | OKC

Mary Shreffler, Pharm.D., BCPS

Clinical Pharmacist OU Health | OKC

Grant Skrepnek, Ph.D., R.Ph.

Professor OU College of Pharmacy | OKC

Taylor Spisany, Pharm.D., BCACP

Clinical Assistant Professor OU College of Pharmacy | OKC

The University of Oklahoma College of Pharmacy has reviewed all faculty and planner financial disclosures and mitigated any relevant financial relationships that exist. Details will be provided to registrants before the activity. No commercial support was received for this program.